公司概覽
業務類別 Biotechnology
業務概覽 Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
公司地址 1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
電話號碼 +1 650 822-5500
傳真號碼 +1 650 636-9773
公司網頁 https://www.annexonbio.com
員工數量 100
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Dean Richard Artis, PhD Executive Vice President and Chief Scientific Officer -- 23/04/2025
Ms. Jennifer Lew Executive Vice President, Chief Financial Officer and Principal Accounting Officer -- 23/04/2025
Dr. Jamie Dananberg, M.D. Executive Vice President and Chief Medical Officer 美元 514.58K 23/04/2025
Mr. Ted Yednock,PhD Executive Vice President and Chief Innovation Officer 美元 478.77K 23/04/2025
Mr. Douglas Love, Esq. President, Chief Executive Officer and Director 美元 641.10K 23/04/2025
Mr. Michael Overdorf Executive Vice President and Chief Business Officer -- 23/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Thomas G. Wiggans Chairman of the Board 17/02/2026
Mr. Muneer A. Satter Independent Director 23/04/2025
Mr. William D. Waddill Independent Director 23/04/2025
Ms. Jung E. Choi Independent Director 23/04/2025
Mr. Douglas Love, Esq. President, Chief Executive Officer and Director 23/04/2025
Dr. William H. Carson, M.D. Independent Director 23/04/2025
Mr. William Jones, Jr Director 10/01/2025
Dr. Bettina M. Cockroft, M.D. Independent Director 23/04/2025
 
所屬ETF (更新日期: 07/03/2026 04:35)
代號 名稱 佔比% 持有日期
VTHRVanguard Russell 3000 ETF0.01%31/01/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%27/02/2026
IBRNiShares Neuroscience and Healthcare ETF0.01%28/02/2026
TMEDT. Rowe Price Health Care ETF0.01%28/02/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%27/02/2026
UWMProShares Ultra Russell20000.004%27/02/2026
URTYProShares UltraPro Russell20000.004%27/02/2026
RFLRInnovator U.S. Small Cp Mgd Flr ETF0.004%25/02/2026
ITWOProShares Russell 2000 High Income ETF0.003%27/02/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.003%28/02/2026
AVUSAvantis US Equity ETF0.003%28/02/2026
GUGGuggenheim Active Allocation Fund0.0001%30/11/2025
HDGProShares Hedge Replication0.0001%27/02/2026
BMEZBlackRock Health Sciences Term Trust<0.000001%31/12/2025
DFATDimensional US Targeted Value ETF<0.000001%17/09/2025
FHLCFidelity MSCI Health Care ETF<0.000001%05/06/2025
ISCBiShares Morningstar Small-Cap ETF<0.000001%20/06/2025
ISCViShares Morningstar Small-Cap Value ETF<0.000001%20/06/2025
SBIOALPS Medical Breakthroughs ETF<0.000001%19/12/2025
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF<0.000001%02/06/2025
  1   2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.